Teicneolaíocht eastóscadh aigéid núicléacha atá bunaithe ar choirníní maighnéadacha: Ceannaireacht na réabhlóide éifeachtúlachta sa tionscal bithchógaisíochta

In the current era of surging demands for precision medicine and large-scale disease screening, a key technology is quietly driving the efficiency revolution in the biopharmaceutical industry – eastóscadh aigéid núicléacha atá bunaithe ar choirníní maighnéadacha. With its significant advantages of high efficiency, uathoibriú, and high purity, this technology has rapidly become an indispensable core tool in molecular diagnostics, seicheamhú géine, and new drug development fields.

Ag baint úsáide as ár n-imoibrithe serum / víreas plasma eastóscadh aigéid núicléacha, Baineadh caolaitheoirí grádán caighdeánach náisiúnta HBV ar an uirlis eastósctha agus íonúcháin uathoibríoch aigéid núicléacha LJbio32H. Braitheadh ​​HBV-qPCR na táirgí a bhaintear as gach caolaitheoir grádán tiúchana, le comhéifeacht comhghaolaithe R>0.99. Seo a leanas na sonraí sonracha:

Anailís ar thorthaí：Tá cruinneas an imoibrí an-ard, agus tá an íogaireacht fós go maith nuair a bhaintear samplaí tiúchan íseal.

Compared with the traditional centrifugal column method, magnetic bead-based extraction achieves rapid separation and purification through the specific binding of nucleic acids to surface-modified magnetic particles under the action of an external magnetic field. This principle enables breakthroughs in throughput, luas, and consistency. Le blianta beaga anuas, this technology has excelled in scenarios such as large-scale screening of infectious diseases (such as COVID-19 nucleic acid testing), tumor liquid biopsy (microscopic ctDNA capture), and genetic disease analysis, effectively supporting high-throughput, standardized modern testing requirements.

Baineadh aigéid núicléacha as rianmhéid na gceall daonna Hela mar shamplaí, 5 cealla, 10 cealla, 20 cealla, 500 Baineadh cealla, agus rinneadh anailís ar na haigéid núicléacha a fuarthas trí úsáid a bhaint as Agilent 4200 Dáileadh blúire aigéid núicléigh, agus tá na torthaí a fuarthas léirithe thíos: 

1. Leictrifheargram na Agilent 4200 Measúnacht Téip Scáileáin RNA Ard-Íogaireachta

D1: 50 cealla HelaG1: 20 cealla HelaB2: 10 cealla HelaE2: 5 cealla Hela

2. Léaráid bhuaic an 50/20/10/5 cealla Hela bhaintear

• Léaráid bhuaic an 5 cealla Hela bhaintear

• . Torthaí tástála Qubit

Níl.	Iontógáil samplach	Toradh(de/μL）
1	50 cealla Hela	0.242
2	20 cealla Hela	0.136
3	10 cealla Hela	0.112
4	5 cealla Hela	0.096

Anailís ar thorthaí： De réir Agilent 4200 is féidir torthaí leictreafóiréis a fheiceáil: 5– 50 rian de shamplaí cealla Hela daonna, Is féidir leis na blúirí aigéid núicléacha a fháil, Ba iad na táirgí eastósctha 18s RNA, 28sRNA, agus DNA os cionn 800bp.

The wave of industry innovation continues to surge. Domestic leading enterprises have launched fully automated solutions integrating magnetic bead extraction, ag baint amach “sample input and result output” in closed tubes, reducing extraction time to minutes and significantly enhancing emergency testing capabilities. Ag an am céanna, breakthroughs in domestic high-end magnetic bead raw materials, such as those from companies like Shanghai Lingjun Biotechnology, have broken the import monopoly, reducing the cost of a single sample by over 30%, significantly enhancing the autonomy of the industrial chain. Capital markets have shown great favor for this sector, with many related enterprises completing large-scale financing recently, driving technological iteration into a fast lane.

Ag féachaint don todhchaí, with the explosion of personalized medical care and immediate testing (POCT) demands, magnetic bead-based technology is evolving towards higher sensitivity, better anti-interference performance, and green biodegradability. Its combination with microfluidics and artificial intelligence is expected to give rise to a new generation of intelligent extraction platforms, continuously providing key infrastructure for the innovation and development of the biopharmaceutical industry.

Soláthraí

Shanghai Lingjun Biteicneolaíocht Co., Teo.bunaíodh i 2016 atá ina mhonaróir gairmiúil d'ábhair bithmhaighnéadacha agus imoibrithe eastóscadh aigéid núicléacha.

Tá taithí shaibhir againn in eastóscadh agus íonú aigéad núicléasach, íonú próitéine, scaradh cille, ceimileacanacht, agus réimsí teicniúla eile.

Úsáidtear ár gcuid táirgí go forleathan i go leor réimsí, mar thástáil leighis, tástáil ghéiniteach, taighde ollscoile, pórú géiniteach, agus mar sin de. Ní chuirimid ar fáil ach táirgí ach freisin is féidir tabhairt faoi OEM, ODM, agus riachtanais eile. Má tá riachtanas gaolmhar agat, bíodh leisce ort teagmháil a dhéanamh linn .